News for BeiGene Ltd (spons. ADRs)

TipRanks 1d

Bernstein Sticks to Their Hold Rating for BeiGene (ONC)

Seeking Alpha 10d

Drugmakers rebound after White House eases fears over Trump’s drug pricing order

TipRanks 10d

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)

TipRanks 14d

BeiGene price target raised to $350 from $348 at Guggenheim

TipRanks 14d

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Generation Bio (GBIO)

TipRanks 14d

RBC Capital Reaffirms Their Buy Rating on BeiGene (ONC)

TipRanks 15d

BeiGene reports Q1 GAAP EPS 1c, consensus (74c)

TipRanks 15d

BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $5.09B

Seeking Alpha 15d

BeiGene reports mixed Q1 results; reaffirms FY25 outlook

Seeking Alpha 16d

BeiGene Q1 2025 Earnings Preview

TipRanks 23d

BeiGene says USPTO invalidates Pharmacyclics’ ‘803 patent

TipRanks 24d

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), BeiGene (ONC) and BioNTech SE (BNTX)

Seeking Alpha 27d

Summit plunges 35%; partner Akesso wins FDA nod for cancer drug

Seeking Alpha 28d

Summit extends gains as cancer drug outperforms BeiGene’s Tevimbra

TipRanks 28d

BeiGene (ONC) Receives a Buy from TD Cowen

Seeking Alpha 41d

AI-focused drug discovery firms rise as FDA phases out animal testing

TipRanks 45d

Reddit initiated, Roku upgraded: Wall Street’s top analyst calls

TipRanks 45d

BeiGene initiated with an Outperform at RBC Capital

Seeking Alpha 49d

BeiGene slips on decision to halt lung cancer program

TipRanks 49d

BeiGene to discontinue development program for ociperlimab (BGB-A1217)

TipRanks 52d

BeiGene receives positive CHMP opinion for Tevimbra

TipRanks 59d

Bank of America Securities Keeps Their Buy Rating on BeiGene (ONC)

TipRanks 70d

BeiGene price target raised to $259 from $207 at Bernstein

Seeking Alpha 79d

BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer

TipRanks 79d

BeiGene announces FDA approval of Tevimbra/chemotherapy combination

TipRanks 80d

BeiGene (ONC) Gets a Buy from J.P. Morgan

TipRanks 80d

BeiGene upgraded to Buy from Neutral at BofA

TipRanks 80d

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BeiGene (ONC) and Omnicell (OMCL)

TipRanks 83d

BeiGene granted orphan designation for sonrotoclax

TipRanks 83d

BeiGene (ONC) Receives a Buy from Morgan Stanley

TipRanks 83d

BeiGene price target raised to $313 from $259 at Macquarie

TipRanks 83d

BeiGene price target raised to $348 from $345 at Guggenheim

TipRanks 83d

BeiGene price target raised to $348 from $288 at Citizens JMP

TipRanks 84d

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC) and Viridian Therapeutics (VRDN)

TipRanks 84d

BeiGene sees FY25 revenue $4.9B-$5.3B, consensus $4.74B

Seeking Alpha 84d

BeiGene reports Q4 results

Seeking Alpha 85d

Here's the major earnings before the open tomorrow

TipRanks 87d

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), BeiGene (ONC) and AptarGroup (ATR)

TipRanks 105d

Wall Street Analysts Are Bullish on Top Healthcare Picks

Seeking Alpha 114d

Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback

TipRanks 115d

BeiGene’s Strategic Growth and Global Expansion Underpin Buy Rating

Seeking Alpha 125d

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

TipRanks 125d

Hold Rating on BeiGene: Balancing Pipeline Progress with Market Challenges

TipRanks 128d

BeiGene’s Path to Financial Stability and Growth: A Buy Recommendation by Jill Wu

TipRanks 140d

Ten new option listings and five option delistings on January 2nd

TipRanks 146d

Netflix draws big viewership for NFL Christmas games: Morning Buzz

TipRanks 146d

Morning Movers: Arena climbs after NYSE acceptance of plan to regain compliance

Seeking Alpha 146d

BeiGene wins FDA nod for Tevimbra in gastric cancer

TipRanks 146d

BeiGene announces FDA approval of Tevimbra

TipRanks 150d

BeiGene to change ticker symbol to ‘ONC’ on January 2, 2025

	
		OSZAR »